N-ацетилцистеин – муколитик и не только...
N-ацетилцистеин – муколитик и не только...
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Синопальников А.И., Клячкина И.Л. Муколитики и отхаркивающие средства. Глава 8 в кн.: Рациональная фармакотерапия заболеваний органов дыхания. М.: Литтерра, 2004.
2. Braga PC, Allegra L. Drugs in Bronchial Mucology. Raven Press, 1989.
3. Sheffner AL et al. the in vitro reduction in viscosity of human tracheobronchial secretions by acetyl-cysteine. Am Rev Resp Dis 1964; 90: 721–9.
4. Lieberman J. Measurement of sputum viscosity in a cone-plate viscometer. Am Rev Respir Dis 1968; 97: 662–72.
5. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine:its reaction with hydrogen peroxide and hypochlorous acid. Free Radic Biol Med 1989; 6 (6): 593–7.
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (Based on the April 1998 NHLBI/WHO Workshop). National Institutes of Health, National Heart. Lung and Blood Institute. April 2001 (Updated 2006).
7. Хроническая обструктивная болезнь легких. Практическое руководство для врачей. Федеральная программа. М., 2004.
8. Grandjean EM et al. efficace of oral term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind placebo-controlled clinical trials. Clin Ther 2000; 22: 209–21.
9. Poole PJ, Black PN. Oral mucolitik drugs for exacerbations of chronik obstructive pulmonary disease: systematic review. BMJ 2001; 322: 1271–4.
10. Stey C, Steurer J, Bachmann S et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. ERJ 2000; 16: 253–62.
11. Decramer M, Rutten-van-Mo..lken M, Dekhuijzen PNR et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS)^ a randomized placebo-controlled trial. Lancet 2005; 365: 1552–60.
12. Maeda H, Akaike T. Oxygen-free radicals as pathogenic molecules in viral diseases. Proc Soc Exp Biol Med 1991; 198: 721–7.
13. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535.
2. Braga PC, Allegra L. Drugs in Bronchial Mucology. Raven Press, 1989.
3. Sheffner AL et al. the in vitro reduction in viscosity of human tracheobronchial secretions by acetyl-cysteine. Am Rev Resp Dis 1964; 90: 721–9.
4. Lieberman J. Measurement of sputum viscosity in a cone-plate viscometer. Am Rev Respir Dis 1968; 97: 662–72.
5. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine:its reaction with hydrogen peroxide and hypochlorous acid. Free Radic Biol Med 1989; 6 (6): 593–7.
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (Based on the April 1998 NHLBI/WHO Workshop). National Institutes of Health, National Heart. Lung and Blood Institute. April 2001 (Updated 2006).
7. Хроническая обструктивная болезнь легких. Практическое руководство для врачей. Федеральная программа. М., 2004.
8. Grandjean EM et al. efficace of oral term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind placebo-controlled clinical trials. Clin Ther 2000; 22: 209–21.
9. Poole PJ, Black PN. Oral mucolitik drugs for exacerbations of chronik obstructive pulmonary disease: systematic review. BMJ 2001; 322: 1271–4.
10. Stey C, Steurer J, Bachmann S et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. ERJ 2000; 16: 253–62.
11. Decramer M, Rutten-van-Mo..lken M, Dekhuijzen PNR et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS)^ a randomized placebo-controlled trial. Lancet 2005; 365: 1552–60.
12. Maeda H, Akaike T. Oxygen-free radicals as pathogenic molecules in viral diseases. Proc Soc Exp Biol Med 1991; 198: 721–7.
13. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535.
Авторы
И.Л.Клячкина
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.